---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-065961"
form_type: "8-K"
ticker: "BTMD"
cik: "0001819253"
company_name: "biote Corp."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:15:04.735393+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biote Q4 revenue $45.7M (+2.7% YoY), net income $12.1M; FY adj. EBITDA $55.3M (+10.2%)

## Summary
- Q4 procedure revenue $34.9M (+6.6%); gross margin 69.4% (up >400 bps); diluted EPS $0.18.
- Full-year revenue $185.4M (+12.4%); net loss $2.8M; adj. diluted EPS $0.13.
- Practitioner network grew to 7,100 from 6,400; launched BioteRx hormone/wellness line.
- Agreed to repurchase 18.4M founders' shares plus separate $20M buyback program.
- Reaffirmed 2024 guidance with expectation of accelerated growth in H2.

## SEC filing metadata
- accession: 0001193125-24-065961
- form_type: 8-K
- ticker: BTMD
- cik: 0001819253
- company_name: biote Corp.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/d759704d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-065961
- JSON: https://secwatch.observer/filing/0001193125-24-065961.json
- Plain text: https://secwatch.observer/filing/0001193125-24-065961.txt

## Key facts
- Earnings Releases
  biote Corp. reported the fourth quarter ended December 31, 2023 results: revenue $45.7 million, net income $12.1 million, EPS $0.18. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $45.7 million
  - Net income: $12.1 million
  - EPS: $0.18
  - Guidance: reaffirmed
  - Result: reported results
  source text: quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior-year period) • Revenue of $45.7 million, a 2.7% increase and in line with pre-released financial guidance • Procedure revenue of $34.9 million, up 6.6% • Gross profit margin of 69.4%, a more than 400-basis point
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm
- Earnings Releases
  biote Corp. reported the full year ended December 31, 2023 results: revenue $185.4 million, net income $(2.8) million, EPS $0.13 per diluted share. Guidance reaffirmed.
  - Period: the full year ended December 31, 2023
  - Revenue: $185.4 million
  - Net income: $(2.8) million
  - EPS: $0.13 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: financial guidance • Adjusted EBITDA margin 1 of 29.7% Full Year 2023 Financial Highlights (All financial result comparisons made are against the prior year) • Revenue of $185.4 million, a 12.4% increase • Procedure revenue of $141.0 million, up 9.3% • Gross profit margin of 68.8%, an approximately 190-basis point increase • Net loss of $(2.8) million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.